Safety, Tolerability, and Pharmacokinetics of RT234 (Vardenafil Inhalation Powder): A First-in-Human, Ascending Single- and Multiple-Dose Study in Healthy Subjects
Authors:
Open Access
- 1 August 2021
- journal article
- research article
- Published by SAGE Publications in Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Vol. 34 (4) , 251-261
Abstract
Background: RT234 (vardenafil inhalation powder) is being developed for pulmonary administration “as needed”, to acutely improve exercise tolerance and symptoms in patients with pulmonary arterial hypertension (PAH). Methods: This single-center, open-label, randomized study in 32 healthy adult subjects evaluated single and multiple inhalation doses of RT234, for safety, tolerability, and pharmacokinetics (PKs). Results: RT234 was generally safe and well tolerated at single doses of 0.2–2.4 mg and after repeated dose administration of up to 2.4 mg q4h for four doses daily for 9 days. The most common treatment-emergent adverse events were mild-to-moderate headaches. There was no evidence of pulmonary irritation or inflammation. Vardenafil was absorbed very rapidly after inhalation as RT234, independent of dose level and number of doses administered. The t max occurred at the time that the first blood sample following completion of dosing. After C max was achieved, plasma vardenafil concentrations declined rapidly in an exponential fashion that appeared to be parallel among dose levels. Vardenafil plasma concentrations and PK parameters increased in a dose-proportional manner. Vardenafil systemic exposure was notably greater after oral administration of 20 mg vardenafil tablets (Levitra ® ) than after administration of any dose level of RT234. During repeated dose administration of RT234, C max was attained rapidly following each dose and in a pattern similar to that observed after single-dose administration. Minor accumulation, characterized by very low mean morning predose vardenafil concentrations (t 1/2 values were comparable after single- and repeated-dose administration. Conclusions: Comparative plasma vardenafil bioavailability data from this study provide scientific justification for reliance on Food and Drug Administration findings for Levitra tablets. These findings support further evaluation of RT234 for as-needed treatment of patients with PAH. The Clinical Trials Registration number is ACTRN12618001077257.Keywords
This publication has 16 references indexed in Scilit:
- The Pharmacological Treatment of Pulmonary Arterial HypertensionPharmacological Reviews, 2012
- Extended Duration of Efficacy of Vardenafil When Taken 8 Hours Before Intercourse: A Randomized, Double-Blind, Placebo-Controlled StudyEuropean Urology, 2006
- Vardenafil Duration of ActionEuropean Urology, 2006
- The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapyInternational Journal Of Impotence Research, 2006
- Maximum likelihood estimation in nonlinear mixed effects modelsComputational Statistics & Data Analysis, 2005
- The Lungs as a Portal of Entry for Systemic Drug DeliveryProceedings of the American Thoracic Society, 2004
- Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5)Neurochemistry International, 2004
- Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertensionJACC, 2004
- Binding of Tritiated Sildenafil, Tadalafil, or Vardenafil to the Phosphodiesterase-5 Catalytic Site Displays Potency, Specificity, Heterogeneity, and cGMP StimulationMolecular Pharmacology, 2004